Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease
NCT ID: NCT05227313
Last Updated: 2022-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2022-03-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status
NCT02046746
Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients
NCT01061320
Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test
NCT04117191
KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.
NCT07260292
Oral Nutritional Supplementation of Hemodialysis Patients
NCT05333692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eefooton oral solution
20ml, 3 times per day (daily dose: 60 ml)
Eefooton oral solution
Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
Placebo oral solution
oral solution matched placebo
Placebo oral solution
oral solution matched placebo
Eefooton oral solution
Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
Placebo oral solution
oral solution matched placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eefooton oral solution
Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
Placebo oral solution
oral solution matched placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Both male and female patients aged 20-85 years old are acceptable
3. You must be able to come back at a specific time each month during the 6-month trial
Exclusion Criteria
2. Heart failure (stage 3-4)
3. Mental illness (psychotic disorder, epilepsy, depression, panic disorder)
4. Patients who have undergone dialysis or are expected to have a kidney transplant in the last three months
5. The blood pressure still exceeds 150/90mmHg after using more than three antihypertensive drugs
6. Pregnancy or planning to become pregnant or breastfeeding
7. Malignant disease
8. Acute illness (hepatitis, jaundice, acute myocardial infarction) in the last 3 months
9. The patient is engaged in another research study.
10. 3 months before entering the study or having used NSAIDs, anti-rejection drugs or performing imaging agent examinations during the study
11. You have participated in other research study in the previous month
12. You have drug dependence and drinking habits
20 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Morris Enterprise Co.,Ltd.
UNKNOWN
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kuo-Cheng Lu, Ph.D
Role: STUDY_CHAIR
Taichung Tzu Chi Hospital
Chen-Shiung Wu, Ph.D
Role: STUDY_DIRECTOR
Taichung Tzu Chi Hospital
Ching-Hsiu Peng, MD
Role: PRINCIPAL_INVESTIGATOR
Taichung Tzu Chi Hospital
Ko-Lin Kuo, MD
Role: PRINCIPAL_INVESTIGATOR
Taichung Tzu Chi Hospital
Yi-Chun Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Taichung Tzu Chi Hospital
Ding-Jun Lin Lin, MD
Role: PRINCIPAL_INVESTIGATOR
Taichung Tzu Chi Hospital
Szu-Chun Hung, MD
Role: PRINCIPAL_INVESTIGATOR
Taichung Tzu Chi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology, Taipei Tzu Chi Hospital, Taipei, Taiwan
Taipei County, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB No.10-FS-088
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.